DFDA

Paroxetine (low-dose)

Treatment for Menopause

Typical Dosage: 7.5mg orally once daily

Effectiveness
70%
Safety Score
60%
Clinical Trials
4
Participants
7.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
7.5mg orally once daily
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
HIGH
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$30,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$636.36
Cost per Remission
$1,400
Paroxetine (low-dose) Outcomes

for Menopause

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Remission Rate
+25%
Common Side Effects
Nausea
+15%
Insomnia/Somnolence
+12%
Fatigue
+8%
Headache
+10%
Dry mouth
+7%
Sexual dysfunction
+7%

Sources:

mdpi.com
nih.gov
tandfonline.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
4 completed trials for Paroxetine (low-dose) in Menopause

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

NCT01829919COMPLETEDPHASE1
View Study
24 participants
INTERVENTIONAL
Baltimore, United States
Started: Jul 1, 2011

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308COMPLETEDPHASE3
View Study
614 participants
INTERVENTIONAL
Mobile, United States +73 more
Started: May 1, 2011

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841COMPLETEDPHASE3
View Study
570 participants
INTERVENTIONAL
Montgomery, United States +31 more
Started: Mar 1, 2010

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

NCT00786188COMPLETEDPHASE2
View Study
102 participants
INTERVENTIONAL
Lake Worth, United States +9 more
Started: Nov 1, 2008